These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 25689806)
1. Clearance of psoriasis: the impact of private versus public insurance. Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158 [TBL] [Abstract][Full Text] [Related]
3. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis. Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729 [TBL] [Abstract][Full Text] [Related]
4. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. Levin AA; Gottlieb AB; Au SC J Drugs Dermatol; 2014 Jul; 13(7):848-53. PubMed ID: 25007369 [TBL] [Abstract][Full Text] [Related]
5. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review. Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734 [TBL] [Abstract][Full Text] [Related]
6. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. Christophers E; Segaert S; Milligan G; Molta CT; Boggs R J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684 [TBL] [Abstract][Full Text] [Related]
7. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254 [TBL] [Abstract][Full Text] [Related]
10. Patient preferences for psoriasis treatments: impact of treatment experience. Schaarschmidt ML; Umar N; Schmieder A; Terris DD; Goebeler M; Goerdt S; Peitsch WK J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):187-98. PubMed ID: 22225546 [TBL] [Abstract][Full Text] [Related]
11. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394 [TBL] [Abstract][Full Text] [Related]
12. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117 [TBL] [Abstract][Full Text] [Related]
13. Predictors of psychiatric boarding in the emergency department. Misek RK; DeBarba AE; Brill A West J Emerg Med; 2015 Jan; 16(1):71-5. PubMed ID: 25671012 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). Lambert J; Ghislain PD; Lambert J; Cauwe B; Van den Enden M J Dermatolog Treat; 2017 Aug; 28(5):394-400. PubMed ID: 27791446 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the adherence and persistence to inhaled corticosteroids among adult patients with public and private drug insurance plans. Cyr MC; Beauchense MF; Lemiere C; Blais L J Popul Ther Clin Pharmacol; 2013; 20(1):e26-41. PubMed ID: 23392860 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. Akasaka E; Mabuchi T; Manabe Y; Yahagi E; Yamada-Hiruma A; Yamaoka H; Kojima T; Kato M; Ikoma N; Ozawa A; Haruki Y J Dermatol; 2013 Apr; 40(4):238-43. PubMed ID: 23330814 [TBL] [Abstract][Full Text] [Related]
17. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece. Souliotis K; Golna C; Kani C; Litsa P J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488 [TBL] [Abstract][Full Text] [Related]
18. Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance. Ivanova JI; Birnbaum HG; Chen L; Duhig AM; Dayoub EJ; Kantor ES; Schiller MB; Phillips GA Am J Manag Care; 2011 Aug; 17(8):e314-23. PubMed ID: 21851139 [TBL] [Abstract][Full Text] [Related]
19. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806 [TBL] [Abstract][Full Text] [Related]
20. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. Armstrong AW; Koning JW; Rowse S; Tan H; Mamolo C; Kaur M Clin Drug Investig; 2017 May; 37(5):493-501. PubMed ID: 28303523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]